

Columbus Office

Vern Riffe Center
77 S. High Street
12th Floor
Columbus, Ohio 43215-6111
(614) 644-5094
Rep46@ohiohouse.gov



Finance

Technology & Innovation

Public Safety

Thomas Hall
State Representative

June 11th, 2025

Rep. Hall HB 263 Sponsor Testimony

Chair Schmidt, Vice Chair Deeter, Ranking Member Somani, and members of the House Health Committee, thank you for the opportunity to provide sponsor testimony on House Bill 263, the Insulin Reduction Act. This legislation came to fruition as a result of personal experience, discussions with healthcare experts, and legislative measures passed by some of our surrounding states.

According to the Ohio Department of Health, more than 12.4% of Ohio adults have been diagnosed with diabetes. Further, according to the American Diabetes Association, the total cost of insulin and other medications that manage blood glucose levels increased by 26% from 2017 to 2022.

As my joint sponsor mentioned, House Bill 363 will cap cost-sharing requirements for insulin at \$35 and at \$100 for diabetes care devices, such as glucose monitors or insulin pumps.

This critical legislation will ultimately expand access to lifesaving medication, ensuring the safety and wellbeing of diabetic Ohioans. Our goal is to put Ohioans first; to make sure that no Ohioan must choose between vital medication or other necessities, such as rent or groceries.

Thank you again for allowing us the opportunity to provide sponsor testimony on House Bill 263. We'd be happy to answer any questions at this time.